Evidence map›Paper›PMID 40194746›Full record

ReviewInternational journal of radiation oncology, biology, physics2025

The Mevalonate Pathway in the Radiation Response of Cancer.

Linda Azizi, Hannah Hausman, Alexandra K Meyer, Matthew Wong, Frank Pajonk

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of radiation oncology, biology, physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Linda AziziDepartment of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California. Electronic address: lindaazizi@g.ucla.edu.
Hannah HausmanDepartment of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
Alexandra K MeyerDepartment of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
Matthew WongDepartment of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.
Frank PajonkDepartment of Radiation Oncology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California; Department of Neurosurgery, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California; Jonsson Comprehensive Cancer Center at University of California, Los Angeles, Los Angeles, California.

Funding

Use of CTEP portfolio compounds to counteract phenotype conversion in GBMR01CA260886 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Frank Pajonk · 2022 to 2026
$2.6M
Utilizing Radiation-Induced Multi-potency to Increase the Efficacy of RadiotherapyR01CA281682 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Frank Pajonk · 2023 to 2026
$2.0M
NCI NIH HHS R01 CA260886NCI NIH HHS R01 CA281682
6 · The paper itself

Abstract

The mevalonate (MVA) pathway plays a critical role in cholesterol biosynthesis, protein prenylation, and metabolic reprogramming, all of which contribute to cancer progression and therapy resistance. Targeting the MVA pathway with statins and other inhibitors has shown promise in preclinical studies; however, clinical outcomes remain controversial, raising concerns about translating these findings into effective treatments. Additionally, the interaction between the MVA pathway and radiation therapy (RT) is not yet fully understood, as RT upregulates the pathway, which can enhance tumor cell survival. This review summarizes the current literature on MVA pathway inhibition in cancer therapy, focusing on its potential to enhance the efficacy of RT. A better understanding of the pathway's role in radiation responses will be essential to translate combination therapies that target this pathway.

Indexed as

Mevalonic AcidNeoplasmsRadiation ToleranceAnimalsCell SurvivalCholesterolHumansHydroxymethylglutaryl-CoA Reductase InhibitorsSignal TransductionCholesterolHydroxymethylglutaryl-CoA Reductase InhibitorsMevalonic Acid

Identifiers

PMID40194746
PMCPMC13171232

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.